Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
| Autor: | Davies, Andrew J *, Caddy, Josh *, McLaughlin, Katy *, Wignall, Christopher *, Waugh, Robert *, Collins, Graham P., Stanton, Louise *, Saunders, Geoff N *, Cummin, Thomas *, Schuh, Anna, Ardeshna, Kirit M., McMillan, Andrew K., Radford, John *, Lewis, David John *, Coleman, Adam R *, Griffiths, Gareth *, Burton, Cathy *, Barrans, Sharon *, Johnson, Peter |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:9478-9479 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|